assessment of minimal residual disease in ewing sarcoma评估尤因肉瘤的微小残留病.pdfVIP

Hindawi Publishing Corporation Sarcoma Volume 2012, Article ID 780129, 8 pages doi:10.1155/2012/780129 Review Article Assessment of Minimal Residual Disease in Ewing Sarcoma Lars M. Wagner,1 Teresa A. Smolarek,2 Janos Sumegi,3 and Daniel Marmer3 1 Division of Pediatric Oncology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA 2 Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA 3 Division of Bone Marrow Transplantation, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA Correspondence should be addressed to Lars M. Wagner, lars.wagner@ Received 15 August 2011; Accepted 27 October 2011 Academic Editor: R. Pollock Copyright © 2012 Lars M. Wagner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Advances in molecular pathology now allow for identification of rare tumor cells in cancer patients. Identification of this minimal residual disease is particularly relevant for Ewing sarcoma, given the potential for recurrence even after complete remission is achieved. Using RT-PCR to detect specific tumor-associated fusion transcripts, otherwise occult tumor cells are found in blood or bone marrow in 20–30% of Ewing sarcoma patients, and their presence is associated with inferior outcomes. Although RT-PCR has excellent sensitivity and specificity for identifying tumor cells, technical cha